Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial bioenergetic machinery is a sophisticated system of membrane-bound protein complexes and enzymes that drive energy production through oxidative phosphorylation (Cook et al., 2017). This machinery primarily includes the electron transport chain (ETC)—comprising NADH dehydrogenases, succinate dehydrogenases, and terminal oxidases like the cytochrome bc1 and cytochrome bd complexes—and the F1Fo-ATP synthase (Hards et al., 2018). These components work in concert to generate a transmembrane electrochemical gradient, known as the proton motive force, which is then utilized by ATP synthase to produce ATP from ADP and inorganic phosphate (NIH, 2013). This system is vital for bacterial growth and survival, particularly for persistent or dormant cells that rely on efficient energy management to withstand environmental stress and antibiotic pressure (Cook et al., 2017). In drug development, the bacterial bioenergetic machinery has emerged as a high-value target space, especially for treating Mycobacterium tuberculosis (Pethe et al., 2013). Inhibitors such as bedaquiline target the ATP synthase, while others like telacebec (Q203) target the cytochrome bc1 complex, leading to energy depletion and bacterial cell death (Cook et al., 2017). Targeting bioenergetics is particularly valuable because it can kill both actively replicating and metabolically dormant bacilli that are often resistant to conventional antibiotics (NIH, 2017).
Inhibition of F1Fo-ATP synthase, inhibition of the cytochrome bc1 complex (QcrB), inhibition of cytochrome bd oxidase, uncoupling of the transmembrane electrochemical gradient (proton motive force), and inhibition of NADH dehydrogenase.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial oxidative phosphorylation system (OXPHOS) (OXPHOS).